Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

M

M.D. Anderson Cancer Center

Other

96

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

127

Indications↗

Distinct diseases across all programs

2,810

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

96 drugs in development

Approved7

Phase 38

Phase 239

Phase 130

Preclinical39

By Therapeutic Area

top 6

Oncology

7763%

Psychiatry

43%

Neurology

43%

Nephrology

32%

Musculoskeletal

32%

Immunology

32%

R&D Momentum

100/100

Pipeline Velocity

98/100

Trial Completion Rate

62/100

Pipeline Concentration

43/100

Pipeline Freshness

40/100

Strategic Signals

↗Active in Infectious Disease but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Active, not recruiting

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Magnetic Resonance Imaging as a Comprehensive Staging Tool for the Evaluation of High-Risk Prostate Carcinoma

Active, not recruiting

A Phase II Multi-Arm Study to Test the Efficacy of Oleclumab and Durvalumab in Multiple Sarcoma Subtypes

A Phase 2 Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Active, not recruiting

A Phase I/II Study of Quizartinib in Combination With Decitabine and Venetoclax for the Treatment of Patients With Acute Myeloid Leukemia (AML)

Active, not recruiting

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Active, not recruiting

A Phase I/II Study of Nivolumab Plus 5-Fluorouracil Plus Interferon-α2b for Unresectable Fibrolamellar Hepatocellular Carcinoma

TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(1 drug)

1

—

—

—

—

Cardiovascular(1 drug)

Gastroenterology(1 drug)

—

—

—

—

1

Gastroenterology(1 drug)

Hematology(2 drugs)

—

—

1

—

1

Hematology(2 drugs)

Immunology(3 drugs)

1

—

1

1

—

Immunology(3 drugs)

Infectious Disease(1 drug)

—

—

—

—

1

Infectious Disease(1 drug)

Musculoskeletal(3 drugs)

1

—

—

1

2

Musculoskeletal(3 drugs)

Nephrology(3 drugs)

—

—

—

—

3

Nephrology(3 drugs)

Neurology(4 drugs)

2

1

—

1

1

Neurology(4 drugs)

Oncology(77 drugs)

27

25

28

4

5

Oncology(77 drugs)

Psychiatry(4 drugs)

2

—

—

—

3

Psychiatry(4 drugs)

Rare Disease(1 drug)

—

—

—

—

1

Rare Disease(1 drug)

Unknown / Other(23 drugs)

10

4

9

1

3

Unknown / Other(23 drugs)

Regulatory

Regulatory Timeline

20181 event

FDADec 20

Asparlas — ASPARLAS

Application BLA761102

20191 event

FDASep 5

Asparlas — ASPARLAS

Application BLA761102

20201 event

FDAJun 24

Asparlas — ASPARLAS

Application BLA761102

20211 event

FDADec 21

Asparlas — ASPARLAS

Application BLA761102

20231 event

FDANov 29

Asparlas — ASPARLAS

Application BLA761102

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)